RT Journal Article
T1 Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
A1 Moreno Márquez, Carolina
A1 Fernández Álvarez, Paula
A1 Valdés Delgado, Teresa
A1 Castro Laria, Luisa
A1 Argüelles Arias, Federico
A1 Caunedo Álvarez, Ángel
A1 Gómez Rodríguez, Blas José
AB the primary goal of this study was to compare gastrointestinal symptom reduction in patients on bismuth-containing quadruple eradication therapy supplemented with Lactobacillus reuteri strains (DSM 17938 and ATCC PTA 6475) or placebo. this was a randomized, double-blind, parallel-arm, placebo-controlled clinical trial. Patients received a first-line eradication regimen based on bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (three-in-one capsules) and omeprazole 40 mg twice a day for ten days, plus a probiotic or placebo tablet for 30 days. During follow-up, gastrointestinal symptoms were assessed using an evaluation scale (GSRS), and adverse events were collected at 0, 14, 28 and 56 days. a total of 80 patients were included from February 2018 to May 2019 at a single site. Eradication therapy was effective in 85 % of patients, with no differences between treatment arms. In the group receiving the probiotic, abdominal pain decreased in 42 % of patients, compared with 19 % in the control group (OR: 0.27; CI, 0.13-0.58; p
SN 1130-0108
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21704
UL http://hdl.handle.net/10668/21704
LA en
DS RISalud
RD Apr 5, 2025